Effects of Second Phases on Microstructure, Microhardness, and Corrosion Behavior of Mg-3Sn-(1Ca) Alloys

The effects of second phases on microstructure, microhardness, and corrosion behavior of aged Mg-3Sn (T3) and Mg-3Sn-1Ca (TX31) alloys are investigated systematically. The thermal stability of the CaMgSn phase is higher than that of the Mg2Sn phase, and the microstructure remains essentially unchanged in the TX31 alloy after solution treatment for 28 h at 733 K. The T3 alloy exhibits double age-hardening peaks; one is 54.9 ± 2.1 HV for 7 h, and the other is 57.4 ± 2.8 HV for 15 h. However, the microhardness quickly reaches a stable value with increasing aging times in the TX31 alloy due to the no change in CaMgSn phases. It was also found by electrochemical impedance spectra that the corrosion resistance of aged T3 alloy is superior to that of aged TX31 alloy, especially T3 alloy aged for 7 h. The corrosion film of aged T3 alloy is denser, which attributes to most of dissolved Sn in the α-Mg matrix and the formation of a small quantity of tiny Mg2Sn particles, and effectively prevents the occurrence of further corrosion of the Mg matrix. However, galvanic cells formed between α-Mg and CaMgSn phases accelerate the corrosion of aged TX31 alloy

Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019 edition)

Abstract The lungs are the second most common site of metastasis for colorectal cancer (CRC) after the liver. Rectal cancer is associated with a higher incidence of lung metastases compared to colon cancer. In China, the proportion of rectal cancer cases is around 50%, much higher than that in Western countries (nearly 30%). However, there is no available consensus or guideline focusing on CRC with lung metastases. We conducted an extensive discussion and reached a consensus of management for lung metastases in CRC based on current research reports and the experts’ clinical experiences and knowledge. This consensus provided detailed approaches of diagnosis and differential diagnosis and provided general guidelines for multidisciplinary therapy (MDT) of lung metastases. We also focused on recommendations of MDT management of synchronous lung metastases and initial metachronous lung metastases. This consensus might improve clinical practice of CRC with lung metastases in China and will encourage oncologists to conduct more clinical trials to obtain high-level evidences about managing lung metastases